Session 7: Recent Advances in Antibody-Drug Conjugates for the Treatment of Cancer
1:20 PM – 2:30 PM
Moderator:
Marco Gottardis, PhD
Janssen Research & Development, LLC
Introduction
Marco Gottardis, PhD
Janssen Research & Development, LLC
Antibody Drug Conjugates: From Early Stage Research to Clinically Approved Drugs
Peter Senter, PhD
Seattle Genetics
Novel Approaches to Development of Antibody-Drug Conjugates for the Treatment of Cancer
Yuuri Hashimoto, PhD
Daiichi Sankyo Co., Ltd.
PSMA Antibody Targeted Amanitin Conjugate (PSMA-ATAC): Introducing a Novel Mode of Action into Prostate Cancer Therap
George Badescu, PhD
Heidelberg Pharma AG
Live Session Discussion
Friday, October 23, 2020